General Information of the Compound
Compound ID
CP0485218
Compound Name
1-(2-Bromo-phenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea
    Show/Hide
Synonyms
1-(2-Bromo-phenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea
1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d][1,2,3]triazol-7-yl)urea
211096-49-0
9P785F0579
AKOS024457259
BCP28242
BDBM50102222
CHEMBL38182
CTK8E9340
DTXSID10175339
J-013849
KB-80496
MolPort-019-939-274
MolPort-044-561-465
N-(2-BROMOPHENYL)-N'-(7-CYANO-1H-BENZOTRIAZOL-4-YL)UREA
NCGC00242491-01
NCGC00242491-02
RT-015648
SB 265610
SB-265610
SB265610, &gt
SCHEMBL1535925
UNII-9P785F0579
Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-be
ZINC603064
sb265610
    Show/Hide
Structure
Formula
C14H9BrN6O
Molecular Weight
357.171
Canonical SMILES
Brc1ccccc1NC(=O)Nc1ccc(C#N)c2nn[nH]c12
    Show/Hide
InChI
InChI=1S/C14H9BrN6O/c15-9-3-1-2-4-10(9)17-14(22)18-11-6-5-8(7-16)12-13(11)20-21-19-12/h1-6H,(H2,17,18,22)(H,19,20,21)
    Show/Hide
InChIKey
SEDUMQWZEOMXSO-UHFFFAOYSA-N
Physicochemical Property
logP
3.23608
Rotatable Bonds
2
Heavy Atom Count
22
Polar Areas
106.49
Hydrogen Bond Donor Count
3
Hydrogen Bond Acceptor Count
4
Complexity
22

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 9841667
SID: 49684220
ChEMBL ID
CHEMBL38182
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01013, C-X-C chemokine receptor type 2
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000043 U2OS Homo sapiens (Human)  1
1
IC50 = 150 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( SB-265610 )
Drug Name SB-265610
Company GlaxoSmithKline
Indication
Asthma
Phase 2
Chronic obstructive pulmonary disease
Discontinued in Phase 1
Target(s)
C-X-C chemokine receptor type 2 (CXCR2)
Antagonist